ga

Skip to content

My Files [0]

These are the files you have added to your collection.

  • You don't have any documents yet, feel free to browse the website and add documents.

CADTH » Search All Products » Therapeutic Reviews » New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation

New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation

CADTH Therapeutic Review

The Canadian Agency for Drugs and Technologies in Health (CADTH) is undertaking a project on the use of new oral anticoagulants in patients with atrial fibrillation, to prevent stroke and other thromboembolic events.

This project will assess the newer oral anticoagulants: dabigatran, rivaroxaban, and apixaban.

The current project has several key components:  

  • Compare the clinical effectiveness and safety of these anticoagulants with warfarin*
  • Determine the cost and economic impact of these anticoagulants compared with warfarin
  • Compare these anticoagulants with optimal warfarin therapy; in other words, consider the impact of the time spent in the therapeutic range (TTR) for patients on warfarin
  • Specifically consider older patients, or patients with other medical conditions or drug therapies
  • Review available strategies to identify over-anticoagulation and bleeding risk with new oral anticoagulants
  • Review available strategies to prevent and treat bleeding associated with new oral anticoagulants
  • Develop recommendations for the use of new oral anticoagulants
  • Determine what tools are available to help health practitioners and consumers manage therapy with new oral anticoagulants and, if needed, develop new tools.

* Warfarin has been the mainstay of oral anticoagulant therapy for more than 60 years. The effectiveness of warfarin for the prevention of stroke in patients with atrial fibrillation is well established. Refer to Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation.

By reviewing the evidence and developing recommendations, CADTH will provide health professionals, policy-makers, and patients with the evidence-based resources they need to make informed decisions.

Feedback Opportunities

Get Involved!

CADTH is seeking feedback from interested stakeholders at key stages during this project:

  1. Draft Science Reports (now closed)
  2. Draft Recommendations (now closed)

Subscribe to the CADTH Communiqué to stay informed about opportunities to provide feedback.   Questions? Email feedback@cadth.ca.